Founded with the mission to revolutionize the treatment of intractable diseases, Time Therapeutics focuses on developing patient-specific induced pluripotent stem (iPS) cell methods. Their core vision is to bring about a drug discovery revolution termed "iPS drug discovery: a dish to bedside," which aims to accurately detect drug efficacy, stratify target patients, and pursue optimal drug pricing. The company is dedicated to providing society with effective treatments for diseases that currently lack fundamental cures.

Time Therapeutics has garnered attention for its innovative approach and has attracted notable investors and collaborators in the biotech industry. The company's key achievements include significant advancements in iPS cell technology and successful preclinical trials demonstrating the potential of their treatments. Through their groundbreaking work, Time Therapeutics is making a substantial impact on the field of regenerative medicine and offering new hope for patients with previously untreatable conditions.